Physician profile
Daniel Kobe
NPI 1073976411
$3,259.50
in general payments reported to CMS, 2019-2025
27 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $172 · 2024: $1,457 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,259.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $494.87 | 2023-2025 | |
| Pfizer INC. | $456.71 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $384.07 | 2024-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $300.39 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $228.62 | 2023-2025 | Lifevest |
| Bridgebio Pharma, INC. | $190.29 | 2025 | Attruby |
| Amgen INC. | $174.49 | 2023-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $168.14 | 2023-2025 | Onpattro |
| Novo Nordisk INC | $149.24 | 2024 | Ozempic |
| Boston Scientific Corporation | $137.32 | 2024-2025 | Watchman Flx, Varithena Administration Pack |
| Kiniksa Pharmaceuticals International, Plc | $89.27 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $56.39 | 2024 | Xarelto |
| Azurity Pharmaceuticals, INC. | $50.61 | 2024 | Edarbi, Edarbyclor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.41 | 2024-2025 | Jardiance |
| Baxter Healthcare | $44.01 | 2025 | Hillrom - Carnation Ambulatory Monitor |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $41.48 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Regeneron Healthcare Solutions, INC. | $35.75 | 2023-2025 | Evkeeza |
| Esperion Therapeutics, INC. | $31.56 | 2024 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $28.42 | 2024 | Farxiga |
| Philips North America LLC | $25.99 | 2024 | (5050) Extended Holter |
| Abiomed | $23.43 | 2025 | |
| Lilly USA, LLC | $21.23 | 2024 | Zepbound |
| Xeris Pharmaceuticals, INC. | $18.96 | 2025 | Keveyis |
| Atricure, INC. | $18.68 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Daiichi Sankyo INC. | $17.00 | 2023 | Injectafer |
| Medicomp INC | $14.33 | 2024 | Telepatch Cardiac Monitor |
| Altathera Pharmaceuticals LLC | $12.84 | 2024 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kobe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.